{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-274856","form_type":"8-K","ticker":"QTTB","cik":"0001661998","company_name":"Q32 Bio Inc.","filed_at":"2024-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.146268+00:00","generated_at":"2026-05-29T04:44:16.816527+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Q32 Bio reports mixed Phase 2a results: AA signal, AD miss","bullets":["SIGNAL-AA: post-hoc analysis showed 16% mean SALT reduction vs 2% placebo at week 24 (p=0.045); 9% vs 0% achieved SALT-20.","SIGNAL-AD Part B failed primary endpoint: bempikibart 74% EASI improvement vs placebo 76% (not statistically significant).","Bempikibart safe and well tolerated in both trials; no SAEs or Grade 3+ related adverse events.","Company plans to enroll ~20 more patients in AA expansion; defers ADX-097 AAV Phase 2 trial to focus on bempikibart.","Biomarker data show robust Th2/Th1 reduction and 20-30% T-cell modulation, confirming target engagement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-274856","json":"https://secwatch.observer/filing/0001193125-24-274856.json","markdown":"https://secwatch.observer/filing/0001193125-24-274856.md","text":"https://secwatch.observer/filing/0001193125-24-274856.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661998/000119312524274856/0001193125-24-274856-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661998/000119312524274856/d903481d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T04:44:16.816527+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}